Detailed disclosure is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported its Q3 FY26 (quarter ended 31 December 2025) and 9M FY26 standalone results, which were approved by the Board and accompanied by an unmodified limited review report from the statutory auditor, Shah Doshi Patel & Associates LLP. Revenue from operations stood at Rs. 122,035 lakhs in Q3, down from Rs. 126,808 lakhs in Q3 FY25 (about 3.8% lower), and at Rs. 360,734 lakhs for 9M FY26 versus Rs. 378,708 lakhs in 9M FY25 (about 4.8% lower). Profit before tax improved to Rs. 11,281 lakhs in Q3 (vs Rs. 9,777 lakhs) and Rs. 28,262 lakhs in 9M (vs Rs. 24,220 lakhs), helped by lower raw material and finance costs, but profit after tax actually fell to Rs. 7,611 lakhs in Q3 (vs Rs. 10,080 lakhs) and Rs. 21,105 lakhs in 9M (vs Rs. 24,126 lakhs) due to much higher current tax outgo this year. Diluted EPS came in at Rs. 0.95 for Q3 and Rs. 2.70 for 9M FY26, down from Rs. 1.36 and Rs. 3.25 respectively a year ago.
A mild topline decline combined with weaker bottom-line print (higher tax pulled PAT down despite better operating profit) is a mixed bag for shareholders — the operating performance looks resilient, but the headline PAT numbers may pressure the stock in the near term until the tax anomaly clarifies. No auditor concerns, no exceptional items, and single-segment pharma reporting keep the disclosure clean.